Skip to Content

Genmab A/S ADR GMAB

Morningstar Rating
$28.49 −0.95 (3.23%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

GMAB is trading at a 14% discount.
Price
$29.36
Fair Value
$51.97
Uncertainty
High
1-Star Price
$11.93
5-Star Price
$34.74
Economic Moat
Pvjy
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GMAB is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$29.44
Day Range
$28.4628.81
52-Week Range
$26.3342.99
Bid/Ask
$28.47 / $28.55
Market Cap
$18.53 Bil
Volume/Avg
115,945 / 607,510

Key Statistics

Price/Earnings (Normalized)
25.44
Price/Sales
8.12
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.42%

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
2,204

Competitors

Valuation

Metric
GMAB
4502
INCY
Price/Earnings (Normalized)
25.4415.7315.11
Price/Book Value
4.100.972.30
Price/Sales
8.121.573.25
Price/Cash Flow
22.228.1716.14
Price/Earnings
GMAB
4502
INCY

Financial Strength

Metric
GMAB
4502
INCY
Quick Ratio
13.320.463.55
Current Ratio
13.341.063.75
Interest Coverage
175.001.93260.45
Quick Ratio
GMAB
4502
INCY

Profitability

Metric
GMAB
4502
INCY
Return on Assets (Normalized)
16.09%2.86%12.82%
Return on Equity (Normalized)
17.97%6.13%16.79%
Return on Invested Capital (Normalized)
15.16%4.78%14.10%
Return on Assets
GMAB
4502
INCY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQqcwzxmqsyQcdq$551.2 Bil
VRTX
Vertex Pharmaceuticals IncZrddtqzgDvjznz$101.9 Bil
REGN
Regeneron Pharmaceuticals IncCsbqwzkTjrfznt$98.1 Bil
MRNA
Moderna IncXwsbfnntpTfdfx$39.7 Bil
ARGX
argenx SE ADRKfnvgrlbzZcr$22.1 Bil
BNTX
BioNTech SE ADRZrcwhnrbFcjhh$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncLjpqyltlDrrcbm$18.6 Bil
BMRN
Biomarin Pharmaceutical IncVmgkxvqhmPkwtg$17.2 Bil
RPRX
Royalty Pharma PLC Class ALzkpxtyhlfBtcwqj$12.3 Bil
INCY
Incyte CorpRpzlfqtDkryc$11.9 Bil

Sponsor Center